National Instruments (NATI) Stock

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS) Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract, further confirm opaganib's protective activity Discussions now ongoing with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which leads the RNCP, regarding plans for the next phase of development along the U.S. Food and Drug Administration's (FDA) Animal Rule pathway to approval TEL AVIV, Israel and RALEIGH, N.C. , Dec. 10, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Silver Storm Mining Ltd. (“Silver Storm” or the "Company") (TSX.V: SVRS | OTCQB: SVRSF | FSE: SVR) announced today that it anticipates the filing of its annual financial statements, management's discussion and analysis and related officer certifications for the financial year ended March 31, 2024 (collectively, the “Annual Filings”) will be delayed beyond the required filing deadline under Parts 4 and 5 of National Instrument 51-102 - Continuous Disclosure Obligations and pursuant to National Instrument 52-109 - Certification of Disclosure in Issuer's Annual and Interim Filings, being July 29, 2024 (the “Filing Deadline”).

CALGARY, AB and SAN ANTONIO, TX / ACCESSWIRE / July 16, 2024 / Nexera Energy Inc. (TSX Venture:NGY)(OTC PINK:EMBYF) (the "Corporation", the "Company" or "Nexera") would like to provide an update on the status of the filing of its annual financial statements, accompanying management's discussion and analysis and related CEO and CFO certifications for the year ended March 31, 2024 (collectively, the "Annual Filings"). The current auditors of the Corporation have recently informed the Corporation that due to the auditors delayed receipt of certain information (such delay a result of (i) certain internal staffing issues at the Corporation that are now resolved; and (ii) internal software issues connected with the Corporation's change of year end (from December 31 to March 31) that are now resolved), they will not be able to complete the audit of the Corporation by the prescribed filing deadline, and the Company anticipates the Annual Filings will be delayed beyond the required filing deadline: (i) under Parts 4 and 5 of National Instrument 51-102 - Continuous Disclosure Obligations and pursuant to National Instrument 52-109 - Certification of Disclosure in Issuer's Annual and Interim Filings, being July 29, 2024 (the "Filing Deadline").

National Instruments Corp's financials are mediocre. Emerson Electronics is acquiring National Instruments to expand its portfolio and gain a competitive advantage in high-margin products and services. National Instruments' financials show below-average performance, but the impending acquisition has rewarded long-term investors.

National Instruments (NATI) came out with quarterly earnings of $0.51 per share, missing the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.36 per share a year ago.

National Instruments (NATI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

In the past year, NATI has rallied 69.75%, in contrast to the SPY's 0.88% decline. This reflects a reversion in NATI's net income - up 56.35% from 2021-22 - in addition to scale growth.

National Instruments (NATI) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.41 per share a year ago.

Emerson Electric just announced a deal to buy National Instruments for $60 a share in cash. The total value of the transaction comes to $8.2 billion.